31 study showed that giving Imfinzi (durvalumab) as adjuvant therapy for stage IB-IIIA non-small cell lung cancer (NSCLC) was no better than placebo at extending disease-free survival (DFS).

“The approval of Imfinzi in this earlier stage of non-small cell lung cancer is a truly meaningful milestone for patients who, until now, had no FDA-approved treatment options following ...

Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use ...

In addition to its indication in LS-SCLC, Imfinzi is the only approved immunotherapy and the global standard of care in the curative-intent setting of unresectable, Stage III NSCLC in patients whose ...

and Imfinzi (durvalumab), within England and Wales’s National Health Service (NHS). Tagrisso has been recommended as an adjuvant therapy following complete surgical resection in adults with stage 1B ...

Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy as neoadjuvant treatment, and then as monotherapy after surgery, is indicated for 'the treatment of adults with resectable (tumours ≥ ...

As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with SCLC, NSCLC, bladder cancer ...

Imfinzi is the global standard of care in the curative-intent setting of unresectable, stage III NSCLC in patients whose disease has not progressed after chemoradiotherapy. It is also approved for ...

Tagrisso has been recommended as an adjuvant therapy following complete surgical resection in adults with stage 1B to 3A non-small cell lung cancer (NSCLC ... Meanwhile, Imfinzi has been ...

The CHMP recommendation is for SC Rybrevant in combination with Lazcluze (lazertinib) for the first-line treatment of patients with advanced NSCLC with ... cancer drug Imfinzi (durvalumab) as ...